WO2024254212A3 - Conjugués anticorps-arn ou -acide nucléique (arc ou anc) anti-vista, compositions les contenant et utilisation thérapeutique associée - Google Patents

Conjugués anticorps-arn ou -acide nucléique (arc ou anc) anti-vista, compositions les contenant et utilisation thérapeutique associée Download PDF

Info

Publication number
WO2024254212A3
WO2024254212A3 PCT/US2024/032660 US2024032660W WO2024254212A3 WO 2024254212 A3 WO2024254212 A3 WO 2024254212A3 US 2024032660 W US2024032660 W US 2024032660W WO 2024254212 A3 WO2024254212 A3 WO 2024254212A3
Authority
WO
WIPO (PCT)
Prior art keywords
ancs
arcs
nucleic acid
acid conjugates
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/032660
Other languages
English (en)
Other versions
WO2024254212A2 (fr
Inventor
Jay ROTHSTEIN
Sergey SEREGIN
Anna KUTA
Xin Huang
Kierstin BELL
Nicholas SCHWERTNER
Catherine CARRIERE
Maria Day
Roman UZHACHENKO
Maheshwerreddy CHILAMARI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lifordi Immunotherapeutics Inc
Original Assignee
Lifordi Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifordi Immunotherapeutics Inc filed Critical Lifordi Immunotherapeutics Inc
Priority to IL325028A priority Critical patent/IL325028A/en
Priority to AU2024285600A priority patent/AU2024285600A1/en
Priority to EP24819971.3A priority patent/EP4713459A2/fr
Publication of WO2024254212A2 publication Critical patent/WO2024254212A2/fr
Publication of WO2024254212A3 publication Critical patent/WO2024254212A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des conjugués anticorps-ARN ou -acide nucléique (ARC ou ANC) anti-VISTA qui délivrent spécifiquement au moins un acide nucléique, par exemple des ARN, dans des cellules immunitaires et l'utilisation de tels ARC ou ANC en tant qu'agents thérapeutiques, par exemple pour le traitement d'états auto-immuns, allergiques et inflammatoires, ou pour le traitement du cancer et/ou pour le traitement de symptômes inflammatoires associés à ceux-ci par des types de cellules immunitaires spécifiques qui expriment VISTA.
PCT/US2024/032660 2023-06-05 2024-06-05 Conjugués anticorps-arn ou -acide nucléique (arc ou anc) anti-vista, compositions les contenant et utilisation thérapeutique associée Ceased WO2024254212A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IL325028A IL325028A (en) 2023-06-05 2024-06-05 Anti-Vista RNA or nucleic acid antibody conjugates (ARCs or ANCs), compositions containing them and their medical use
AU2024285600A AU2024285600A1 (en) 2023-06-05 2024-06-05 Anti-vista antibody rna or nucleic acid conjugates (arcs or ancs), compositions containing, and therapeutic use thereof
EP24819971.3A EP4713459A2 (fr) 2023-06-05 2024-06-05 Conjugués anticorps-arn ou -acide nucléique (arc ou anc) anti-vista, compositions les contenant et utilisation thérapeutique associée

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363506177P 2023-06-05 2023-06-05
US63/506,177 2023-06-05
US202363611302P 2023-12-18 2023-12-18
US63/611,302 2023-12-18

Publications (2)

Publication Number Publication Date
WO2024254212A2 WO2024254212A2 (fr) 2024-12-12
WO2024254212A3 true WO2024254212A3 (fr) 2025-02-20

Family

ID=93794697

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/032660 Ceased WO2024254212A2 (fr) 2023-06-05 2024-06-05 Conjugués anticorps-arn ou -acide nucléique (arc ou anc) anti-vista, compositions les contenant et utilisation thérapeutique associée

Country Status (4)

Country Link
EP (1) EP4713459A2 (fr)
AU (1) AU2024285600A1 (fr)
IL (1) IL325028A (fr)
WO (1) WO2024254212A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190330349A1 (en) * 2016-04-15 2019-10-31 Immunext, Inc. Anti-human vista antibodies and use thereof
WO2022115719A1 (fr) * 2020-11-30 2022-06-02 Fred Hutchinson Cancer Research Center Peptides se liant à pd-l1, complexes peptidiques et leurs méthodes d'utilisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190330349A1 (en) * 2016-04-15 2019-10-31 Immunext, Inc. Anti-human vista antibodies and use thereof
WO2022115719A1 (fr) * 2020-11-30 2022-06-02 Fred Hutchinson Cancer Research Center Peptides se liant à pd-l1, complexes peptidiques et leurs méthodes d'utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KUMAR PRITI: "T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice.", CELL, vol. 134, no. 4, 22 August 2008 (2008-08-22), US , pages 577 - 586, XP002499772, ISSN: 1097-4172, DOI: 10.1016/J.CELL.2008.06.034 *
SONG: "Antibody mediated in vivo delivery of small interfering RNAs via cell -surface receptors", NATURE BIOTECHNOLOGY, 10 August 2024 (2024-08-10), pages 709 - 717, DOI: 10.1038/nbt1101 *
WIENER JULIUS, KOKOTEK DANIEL, ROSOWSKI SIMON, LICKERT HEIKO, MEIER MATTHIAS: "Preparation of single- and double-oligonucleotide antibody conjugates and their application for protein analytics", SCIENTIFIC REPORTS, vol. 10, no. 1, 1 December 2020 (2020-12-01), pages 1 - 11, XP055881757, DOI: 10.1038/s41598-020-58238-6 *

Also Published As

Publication number Publication date
AU2024285600A1 (en) 2026-01-08
WO2024254212A2 (fr) 2024-12-12
IL325028A (en) 2026-01-01
EP4713459A2 (fr) 2026-03-25

Similar Documents

Publication Publication Date Title
ES2962434T3 (es) Procedimientos y composiciones para editar ARN
US20220307020A1 (en) Methods and compositions for editing rnas
CN105886534A (zh) 一种抑制肿瘤转移的方法
MX2022003116A (es) Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos.
WO2010041913A3 (fr) Nouvelles utilisations des protéines grs ou de leurs fragments
WO2020219682A3 (fr) Knock-out de gènes pour améliorer la fonction des lymphocytes t
EA201591590A1 (ru) Модифицированные олигонуклеотиды трф-бета
UA118014C2 (uk) Спосіб модифікації днк-мішені
WO2007038637A3 (fr) Anticorps monoclonaux humains diriges contre cd70
MX336623B (es) Peptidos penetradores de las celulas y usos de los mismos.
MA33276B1 (fr) Anticorps spécifiques à la cadhérine-17
CA2796722C (fr) Compositions et procedes permettant l'administration selective de molecules d'oligonucleotides a des types de neurones specifiques
EP2468773A3 (fr) Anticorps anti-GM-CSF et utilisations associées
GB2453068A (en) Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
WO2010011315A3 (fr) Protéines pour utilisation dans le diagnostic et le traitement d'une infection et d'une maladie
WO2006086673A3 (fr) Compositions nucleotidiques et utilisations de celles-ci
Cha et al. Cathepsins in the kidney of olive flounder, Paralichthys olivaceus, and their responses to bacterial infection
WO2021222065A8 (fr) Compositions d'agent d'arni de l'apolipoprotéine e (apoe) et leurs procédés d'utilisation
WO2023034837A3 (fr) Compositions d'arni d'effecteur de type dffa induisant la mort cellulaire b (cideb) et leurs méthodes d'utilisation
AU2024312860A1 (en) Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
ZA202209180B (en) Compositions and methods for treating long covid
WO2024254212A3 (fr) Conjugués anticorps-arn ou -acide nucléique (arc ou anc) anti-vista, compositions les contenant et utilisation thérapeutique associée
WO2024137700A3 (fr) Molécules d'acide polynucléique ciblant l'agt et leurs utilisations
WO2007022121A3 (fr) Composes o-nitro, compositions pharmaceutiques correspondantes, et leurs utilisations
WO2010123798A3 (fr) Compositions de transfection de biomolécules dans des cellules

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: MX/A/2025/014613

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: AU2024285600

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 827852

Country of ref document: NZ

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025026579

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2024819971

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 827852

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020267000253

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024285600

Country of ref document: AU

Date of ref document: 20240605

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2024819971

Country of ref document: EP

Effective date: 20251218

ENP Entry into the national phase

Ref document number: 2024819971

Country of ref document: EP

Effective date: 20251218

ENP Entry into the national phase

Ref document number: 2024819971

Country of ref document: EP

Effective date: 20251218

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24819971

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 11202508210W

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 11202508210W

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 2024819971

Country of ref document: EP

Effective date: 20251218

ENP Entry into the national phase

Ref document number: 2024819971

Country of ref document: EP

Effective date: 20251218